Full-Time

Professional Aesthetic Consultant

Posted on 3/27/2025

Revance

Revance

501-1,000 employees

Biotechnology company for aesthetic solutions

Compensation Overview

$95k - $105k/yr

+ Commission

Mid, Senior

Tyler, TX, USA

The job is focused on the East Texas region, specifically targeting customers in that area.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Lead Generation
Requirements
  • Master’s degree or Bachelor’s degree & 2 years of sales experience
Responsibilities
  • Strategically manages the territory to meet or exceed sales objectives.
  • Responsible for lead generation through direct contact with customers in assigned area.
  • Maintains effective customer relations, develops opportunities for growth within an existing customer base, and assures market penetration and profitability while achieving sales forecasts.
  • Delivers sales results per assigned quarterly goals, and have primary responsibility for area metrics, issues and customers.
  • Maintains a pipeline of opportunities to meet or exceed sales objectives.
  • Provides and filters key market insights back to sales and marketing management.
  • Maintains accurate reporting, records and files necessary for proper management of territory.
  • Positively represents Revance throughout customer locations.
  • Actively participates in sales meetings, conference calls, and other necessary business meetings.
  • Demonstrates honesty and integrity while modeling behaviors consistent with company standards, and adheres to all sales policies and procedures.
Desired Qualifications
  • Bachelor’s degree and minimum 2 years of sales experience
  • 5+ years of sales/account management experience a plus
  • History of meeting and exceeding sales objectives.
  • Experience in medical aesthetics, dermatology, or plastic surgery a plus
  • Launch experience.
  • Experience in buy and bill or cash pay medicine a plus
  • Advanced business acumen; understands competitors, influencers and industry trends.
  • Ability to work in a launch or fast-paced, highly visible and dynamic environment.
  • Strong knowledge of analytics, budgeting and key revenue drivers; able to leverage data to target and prioritize opportunities.
  • A valid driver’s license is required

Revance Therapeutics, Inc. specializes in aesthetic and therapeutic solutions, primarily focusing on products that enhance physical appearance and improve patient outcomes. The company offers neuromodulators, like botulinum toxin type A, which reduce wrinkles and treat muscle movement disorders, and dermal fillers that restore volume and smooth facial lines. Revance is also exploring therapeutic uses for its products to address muscle movement and pain disorders. Additionally, the company has expanded into the fintech sector with the acquisition of HintMD, a platform that streamlines payment processes for aesthetic practices. This integration allows Revance to provide a comprehensive suite of services to support aesthetic practitioners. Unlike its competitors, Revance emphasizes differentiated products and improved patient experiences, aiming to establish itself as a leader in the premium aesthetics market.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in minimally invasive procedures benefits Revance's aesthetic product offerings.
  • Fintech integration in aesthetics enhances customer satisfaction and retention for Revance.
  • Global botulinum toxin market growth supports Revance's neuromodulator product expansion.

What critics are saying

  • Evolus's Jeuveau targets younger demographics, potentially capturing Revance's market share.
  • Class action lawsuit poses financial liabilities and reputational damage to Revance.
  • Minimum purchase obligations under Distribution Agreement present financial risks for Revance.

What makes Revance unique

  • Revance integrates fintech solutions like HintMD to streamline aesthetic practice payments.
  • The company focuses on innovative neuromodulators and dermal fillers for aesthetic treatments.
  • Revance targets personalized medicine trends with differentiated dermatology and aesthetic products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Unlimited Paid Time Off

401(k) Company Match

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

0%
Finimize
Mar 5th, 2025
Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment

Evolus has strategically targeted a younger audience with its wrinkle treatment Jeuveau, setting itself apart from competitors like Revance and AbbVie, which usually focus on clients in their 40s.

GlobeNewswire
Feb 4th, 2025
RVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

In addition, under the Distribution Agreement, Revance is required to meet certain minimum purchase obligations and certain minimum expenditure requirements and either party may terminate the Distribution Agreement in the event of "a material breach by the other party."

PR Newswire
Jan 31st, 2025
Revance Stockholders Urged To Tender Their Shares In Support Of Crown Transaction By The February 4Th Deadline

Crown offer of $3.65 per share is the only offer available to Revance stockholders. Crown offer unanimously approved by the Revance Board of Directors. Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender

Bizjournals
Jan 30th, 2025
Revance Therapeutics to Go Private at $3.65

Revance Therapeutics is set to go private with Crown Laboratories by Feb. 6. Crown has increased its offer to $3.65 per share, a 17% rise from the previous $3.10 offer. The deal, endorsed by Revance's board, is the only fully-financed offer available. The initial $6.66 offer was paused due to a breach with Teoxane, but a settlement has been reached. Revance's shares were trading at $3.63, with a 52-week range of $2.30-$7.56. The offer is valid until Feb. 4.

Teknovation
Jan 27th, 2025
News & Notes | Acting Administrator Of National Nuclear Security Administration Has Oak Ridge Ties

From Washington, DC but with Oak Ridge ties: Teresa Robbins has been named as the Acting Administrator of the National Nuclear Security Administration (NNSA). Prior to this, she served as... The post News Notes | Acting Administrator of National Nuclear Security Administration has Oak Ridge ties appeared first on Teknovation.biz.

INACTIVE